stockrowBoston Scientific Corporation
BSX Healthcare Medical Devices
Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024.
- Revenue
- +1.44%
- EPS
- −21.6%
- Free cash flow
- −25.3%
- Total debt
- +3.04%
Quarter to September 2026, against a year earlier
Follow BSX
Alert me
Boston Scientific Corporation (BSX) Return on equity
Boston Scientific Corporation's return on equity over the twelve months to 30 September 2026 was 14.2%, up 1.7 percentage points from fiscal 2025 (12.5%). Over the past ten years it has ranged from −3.74% (fiscal 2015) to 41.6% (fiscal 2019); the current reading is higher than 82% of that period. That is above the Medical Devices industry median of −10.4% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 12.5% | 3.55 |
| FY2024 | 8.92% | 0.46 |
| FY2023 | 8.46% | 4.71 |
| FY2022 | 3.75% | (2.42) |
| FY2021 | 6.17% | 6.96 |
| FY2020 | −0.79% | (42.38) |
| FY2019 | 41.6% | 20.35 |
| FY2018 | 21.2% | 19.73 |
| FY2017 | 1.51% | (3.81) |
| FY2016 | 5.32% | 9.06 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| DXCM DexCom, Inc. compare | 37.7% |
| GEHC GE HealthCare Technologies Inc. compare | 19.9% |
| SYK Stryker Corporation compare | 16.0% |
| BSX Boston Scientific Corporation | 14.2% |
| STE STERIS plc compare | 11.6% |
| MDT Medtronic PLC compare | 10.6% |
| EW Edwards Lifesciences Corporation compare | 9.65% |
| PHG Koninklijke Philips N.V. compare | 8.54% |
| ABT Abbott Laboratories compare | 0.00% |
| Medical Devices industry median | −10.4% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on BSX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement